Wilmington, DE -- (SBWIRE) -- 12/09/2013 -- Equity Profile Report expands its NASDAQ Active Stock Weekly Watch List adding Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) and Celgene Corporation (NASDAQ:CELG).
Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) a biopharmaceutical company that engages in discovering, developing, and commercializing novel drugs that target G protein-coupled receptors in the therapeutic areas of cardiovascular, central nervous system, inflammatory, and metabolic diseases closed down in its previous session (-4.03%) on 4,826,218 shares traded after Arena Pharmaceuticals Management Presented at Piper Jaffray 2013 Healthcare Conference. Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) is currently down (-46.36%) from its recent 52-week high which has prompted Equity Profile Report to add the stock to their NASDAQ Active Stock Watch List.
Click Here to find out what other Investors are saying about Arena Pharmaceuticals, Inc. (NASDAQ:ARNA)
Celgene Corporation (NASDAQ:CELG) a company that discovers, develops, and commercializes therapies for cancer and immune-inflammatory related diseases in the United States and Europe closed up in its previous session (+1.17%) on 2,547,011 shares traded after a UBS analyst upgraded the biotechnology company, forecasting strong net income growth. Celgene Corporation (NASDAQ:CELG) is currently up (+116.59%) from its recent 52-week low which has prompted Equity Profile Report to add the stock to their NASDAQ Active Stock Watch List.
Click Here to find out what other Investors are saying about Celgene Corporation (NASDAQ:CELG)
Equityprofilereport.com monitors and scans the markets for stock related signals as well as any external factors that might bring trading opportunities.
Through a vast network of IR professionals Equityprofilereport.com is often aware of several large investor awareness campaigns being deployed.
Timing is important when trading Small Caps and Penny Stocks.
Simply sign up for free and start receiving exclusive alerts.
Subscribe Here: http://www.Equityprofilereport.com
Equityprofilereport.com is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell securities. Investors should always conduct their own due diligence with any potential investment. Please visit Equityprofilereport.com website, for complete risks and disclosures.
Equity Profile Report